Literature DB >> 6198631

Adenosine deaminase (ADA) deficiency in cells derived from humans with severe combined immunodeficiency is due to an aberration of the ADA protein.

D Valerio, M G Duyvesteyn, H van Ormondt, P Meera Khan, A J van der Eb.   

Abstract

In order to determine the molecular basis of adenosine deaminase (ADA) deficiency in cells derived from patients with severe combined immunodeficiency (SCID) disease, we used a human ADA cDNA clone (1) to analyse the organization and transcription of the ADA gene in both normal and ADA-SCID cells. In five lymphoblastoid ADA-SCID cell lines we could detect no deletions or rearrangements in the ADA gene and its flanking sequences. Furthermore, synthesis and processing of ADA mRNA appeared to be normal in the ADA-SCID cells, and ADA-specific mRNA from two ADA-SCID cells could be translated in vitro into a protein with the molecular weight of normal ADA; this protein, however, could hardly be precipitated with an ADA antiserum. The results indicate that in these two ADA-SCID cell lines, the lack of ADA activity is not due to transcriptional or translational defects, but to subtle changes in the configuration of the protein affecting both its enzymatic and immunological characteristics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198631      PMCID: PMC318552          DOI: 10.1093/nar/12.2.1015

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  13 in total

1.  Human adenosine deaminase. Purification and subunit structure.

Authors:  P E Daddona; W N Kelley
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

2.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

Review 3.  Adenosine deaminase deficiency and severe combined immunodeficiency disease.

Authors:  L F Thompson; J E Seegmiller
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1980

4.  Human adenosine deaminase. Properties and turnover in cultured T and B lymphoblasts.

Authors:  P E Daddona
Journal:  J Biol Chem       Date:  1981-12-10       Impact factor: 5.157

5.  Characterization of cells transformed by Ad5/Ad12 hybrid early region I plasmids.

Authors:  R Bernards; A Houweling; P I Schrier; J L Bos; A J Van der Eb
Journal:  Virology       Date:  1982-07-30       Impact factor: 3.616

6.  Immunoreactive protein in adenosine deaminase deficient human lymphoblast cell lines.

Authors:  D A Wiginton; J J Hutton
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

7.  Characteristics of an aminohydrolase distinct from adenosine deaminase in cultured human lymphoblasts.

Authors:  P E Daddona; W N Kelley
Journal:  Biochim Biophys Acta       Date:  1981-04-14

8.  Adenosine deaminase messenger RNAs in lymphoblast cell lines derived from leukemic patients and patients with hereditary adenosine deaminase deficiency.

Authors:  G S Adrian; J J Hutton
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

9.  Characterization of residual enzyme activity in fibroblasts from patients with adenosine deaminase deficiency and combined immunodeficiency: evidence for a mutant enzyme.

Authors:  R Hirschhorn; N Beratis; F S Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1976-01       Impact factor: 11.205

10.  Erythrocyte adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme.

Authors:  R Hirschhorn; V Roegner; T Jenkins; C Seaman; S Piomelli; W Borkowsky
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

View more
  15 in total

Review 1.  The map of chromosome 20.

Authors:  N E Simpson
Journal:  J Med Genet       Date:  1988-12       Impact factor: 6.318

2.  Structure of adenosine deaminase mRNAs from normal and adenosine deaminase-deficient human cell lines.

Authors:  G S Adrian; D A Wiginton; J J Hutton
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

3.  Activity of the adenosine deaminase promoter in transgenic mice.

Authors:  D Valerio; H van der Putten; F M Botteri; P M Hoogerbrugge
Journal:  Nucleic Acids Res       Date:  1988-11-11       Impact factor: 16.971

Review 4.  Diagnosis of genetic disease using recombinant DNA.

Authors:  D N Cooper; J Schmidtke
Journal:  Hum Genet       Date:  1986-05       Impact factor: 4.132

5.  Partial adenosine deaminase deficiency: another family from southern Africa.

Authors:  S L Hart; A B Lane; T Jenkins
Journal:  Hum Genet       Date:  1986-11       Impact factor: 4.132

6.  Severe combined immune deficiency due to a homozygous 3.2-kb deletion spanning the promoter and first exon of the adenosine deaminase gene.

Authors:  T M Berkvens; E J Gerritsen; M Oldenburg; C Breukel; J T Wijnen; H van Ormondt; J M Vossen; A J van der Eb; P Meera Khan
Journal:  Nucleic Acids Res       Date:  1987-11-25       Impact factor: 16.971

7.  Adenosine deaminase mRNA expression is regulated posttranscriptionally during differentiation of HL-60 cells.

Authors:  T M Berkvens; F Schoute; H van Ormondt; P M Khan; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1987-08-25       Impact factor: 16.971

8.  Transient expression of human adenosine deaminase cDNAs: identification of a nonfunctional clone resulting from a single amino acid substitution.

Authors:  S H Orkin; S C Goff; W N Kelley; P E Daddona
Journal:  Mol Cell Biol       Date:  1985-04       Impact factor: 4.272

9.  Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency.

Authors:  D T Bonthron; A F Markham; D Ginsburg; S H Orkin
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

10.  Adenosine deaminase gene expression is regulated posttranscriptionally in the nucleus.

Authors:  T M Berkvens; F Schoute; H van Ormondt; P Meera Khan; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1988-04-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.